The University of Chicago Header Logo

Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience.

Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020 01; 20(1):95-104.

View in: PubMed